Indivior Announces Inclusion in the S&P SmallCap 600® Index

Rhea-AI Summary

Indivior (Nasdaq: INDV) announced it was added to the S&P SmallCap 600 index, effective December 22, 2025. The company said the inclusion aligns its capital markets presence with a sharpened U.S. business profile and supports growth of SUBLOCADE, its first‑in‑class long‑acting injectable for moderate to severe opioid use disorder.

The S&P SmallCap 600 tracks 600 U.S. small‑cap companies with market capitalizations generally between $1.2 billion and $8.0 billion and applies liquidity and viability criteria for inclusion.

Positive

• Added to S&P SmallCap 600 effective Dec 22, 2025
• Index inclusion aligns capital markets presence with U.S. business profile
• SUBLOCADE identified as company’s number one prescribed OUD treatment

Negative

• None.

News Market Reaction – INDV

+3.52%

+3.52% Session close to close

In the Dec 22 session, INDV gained 3.52%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds Indivior to the S&P SmallCap 600®, a benchmark of 600 U.S. small‑cap companie...

Analysis

This announcement adds Indivior to the S&P SmallCap 600®, a benchmark of 600 U.S. small‑cap companies with market capitalizations between $1.2 billion and $8.0 billion. It follows recent milestones including raised 2025 guidance, positive SUBLOCADE data, and the conclusion of a DOJ matter. Investors may watch how index inclusion affects liquidity and ownership, while monitoring execution on the simplified operating model and ongoing restructuring and redomiciling plans.

Key Figures

Index constituents: 600 companies Index min market cap: $1.2 billion Index max market cap: $8.0 billion

3 metrics

Index constituents 600 companies Number of companies in the S&P SmallCap 600 index

Index min market cap $1.2 billion Lower end of market capitalization range for S&P SmallCap 600

Index max market cap $8.0 billion Upper end of market capitalization range for S&P SmallCap 600

Historical Context

5 past events · Latest: Dec 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 17	Clinical trial data	Positive	+1.6%	SUBLOCADE trial showed rapid, meaningful reductions in opioid use and good safety.
Nov 20	Legal resolution	Positive	-2.5%	Paid remaining $295 million DOJ obligation in full, concluding legacy matter.
Nov 19	Conference participation	Neutral	+1.1%	Announced participation and investor meetings at Piper Sandler healthcare conference.
Nov 03	Real-world evidence	Positive	+6.2%	Presented data showing lower relapse rates and medical costs with SUBLOCADE adherence.
Oct 30	Earnings and guidance	Positive	+15.4%	Q3 2025 beat with SUBLOCADE growth and raised 2025 revenue and EBITDA guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has generally seen positive price alignment, especially for earnings and clinical or real‑world data, with one divergence on the DOJ resolution headline.

Recent Company History

Over the last few months, Indivior reported multiple positive catalysts, including strong Q3 2025 results with raised full‑year guidance on Oct 30, 2025 and supportive real‑world and clinical data for SUBLOCADE. The stock reacted strongly to earnings, rising 15.41%, and gained 6.23% on real‑world evidence presented on Nov 3, 2025. A DOJ matter conclusion on Nov 20, 2025 led to a ‑2.55% move despite removing a liability. Today’s S&P SmallCap 600® inclusion follows this series of operational and legal milestones.

Key Terms

s&p smallcap 600, long-acting injectable, opioid use disorder, market capitalizations

4 terms

s&p smallcap 600 technical

"it will be added to the S&P SmallCap 600® index, effective today."

A stock market index made up of 600 small-cap U.S. companies chosen to represent the performance of smaller publicly traded firms. It matters to investors because it acts like a temperature gauge for the small-company segment of the market, serving as a benchmark for fund managers, a basis for index funds and ETFs, and a way to compare returns and risk when building a diversified portfolio.

long-acting injectable medical

"first-in-class long-acting injectable treatment for moderate to severe opioid use disorder"

A long-acting injectable is a medication formulated to be given by shot that releases its active ingredient slowly over weeks or months so a patient needs fewer doses. For investors, these products can change a drug’s market value by improving patient convenience and adherence, extending patent life or pricing opportunities, and requiring different manufacturing and regulatory steps compared with daily pills — much like swapping many small payments for a single, larger subscription.

opioid use disorder medical

"treatment for moderate to severe opioid use disorder, as we leverage our new"

Opioid use disorder is a medical condition where a person repeatedly seeks and uses opioid drugs despite harmful physical, social or mental effects, often involving strong cravings and withdrawal symptoms when stopping. It matters to investors because its prevalence, availability of effective treatments, regulatory responses, and legal or insurance costs can shift demand, revenue and risk across drug makers, treatment providers and insurers—like a widespread problem that reshapes an entire market.

market capitalizations financial

"with market capitalizations between $1.2 billion and $8.0 billion."

Market capitalizations measure the total value investors place on a publicly traded company by multiplying its current share price by the total number of shares outstanding. It matters because it gives a quick sense of a company's size and risk profile—smaller market caps are often seen as more volatile but with bigger growth potential, while larger ones tend to be steadier—so investors use it to compare companies and build diversified portfolios, like comparing the total worth of different-sized businesses in a town.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RICHMOND, Va., Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600^® index, effective today.

"Indivior's inclusion in the S&P SmallCap 600 index marks an important milestone for Indivior that further aligns our capital markets presence with our sharpened U.S. business profile," said Joe Ciaffoni, Chief Executive Officer. "We are committed to growing SUBLOCADE^®, our number one prescribed, first-in-class long-acting injectable treatment for moderate to severe opioid use disorder, as we leverage our new and simplified operating model."

The S&P SmallCap 600 Index is a stock market index established by Standard & Poor's that is designed to measure the performance of the small-cap segment of the market and is composed of 600 constituent companies in the U.S. equities market with market capitalizations between $1.2 billion and $8.0 billion. The index is designed to track companies that meet specific inclusion criteria to ensure that they are liquid and financially viable. For more information on the S&P SmallCap 600 and S&P Dow Jones Indices, please visit www.spdji.com.

About Indivior

Indivior Pharmaceuticals works to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease. Building on its portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-inclusion-in-the-sp-smallcap-600-index-302647090.html

SOURCE Indivior PLC

FAQ

What does Indivior (INDV) joining the S&P SmallCap 600 mean for shareholders?

Indivior's inclusion on Dec 22, 2025 means the stock becomes a constituent of the S&P SmallCap 600, aligning its market profile with other small‑cap companies.

When did Indivior (INDV) officially join the S&P SmallCap 600 index?

Indivior was added to the S&P SmallCap 600 effective December 22, 2025.

What market capitalization range applies to S&P SmallCap 600 constituents?

The S&P SmallCap 600 typically includes companies with market capitalizations between $1.2 billion and $8.0 billion.

How does Indivior describe the impact of the index inclusion on its U.S. business?

The company said inclusion further aligns its capital markets presence with its sharpened U.S. business profile and supports growth plans for SUBLOCADE.

Will Indivior (INDV) inclusion in the S&P SmallCap 600 affect liquidity and visibility?

Inclusion in the S&P SmallCap 600 is intended to reflect companies that meet liquidity and financial viability criteria, which can increase visibility among investors.

Where can investors find more information about the S&P SmallCap 600 and Indivior?

Investors can visit www.spdji.com for S&P index details and www.indivior.com for company information.